ArticleClinical ophthalmology (Auckland, N.Z.)2025
Clinical Outcomes of Descemet Membrane Endothelial Keratoplasty in Saudi Patients.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Descemet membrane endothelial keratoplasty (DMEK) is a well-known surgical procedure for managing corneal endothelial diseases. However, the applicability of DMEK across different populations remains unclear. This study aimed to evaluate the outcomes of DMEK in patients from Saudi Arabia and compare them with international standards. Patients and Methods: This retrospective record review evaluated the medical records of 12 patients who underwent DMEK at King Abdulaziz University Hospital from October 2022 to December 2023. Postoperative outcomes, including best-corrected visual acuity, intraocular pressure (IOP), graft attachment, and rates of rejection and re-bubbling, were evaluated at the 1-month follow-up visit. Results: Of the 12 patients, 10 were included in the final analysis (mean age, 65.5 ± 8.69 years; men, n = 3, 30%; women, n = 7, 70%). The most common indications for DMEK were pseudophakic bullous keratopathy (50%) and Fuchs' endothelial corneal dystrophy (40%). Postoperatively, the median best-corrected visual acuity improved significantly from 0.5 (range, 0.5-1) to 0.1 (range, 0.1-0.3) (P = 0.039). The median IOP remained stable, with no significant change observed postoperatively. None of the patients experienced graft rejection or failure; however, 20% required re-bubbling. The mean central corneal thickness significantly decreased from 676 ± 103.71 μm preoperatively to 506.2 ± 27.57 μm postoperatively (P < 0.001). Conclusion: This study demonstrated that DMEK provides effective visual improvement with low complication rates in patients from Saudi Arabia, comparable to the findings obtained in international studies. These findings may encourage wider adoption of DMEK among corneal surgeons in Saudi Arabia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.